Access Pharmaceuticals today said that Dr. Ron R. Allison of Carolina Radiation Medicine, Greenville, NC, recently presented results from the company’s ongoing MuGard phase 4 clinical trial in oral mucositis at the Multinational Association of Supportive Care in Cancer (MASCC) Conference in NYC, presenting summarized data from 70 cancer patients undergoing chemoradiation therapy for head and neck cancer.
Data shows that patients using MuGard experienced statistically significant efficacy in: reduction in mouth and throat pain, a common side effect of chemotherapies; a delay to onset of oral mucositis, a debilitating side effect of some radiation and chemotherapy cancer treatments; and reductions in weight loss during therapy and in the use of opioid pain medication.
“Given the significant oral mucositis typically seen in this head and neck cancer population, the benefits of MuGard shown in the results from this trial are important both clinically and from a patient quality-of-life perspective. It’s critically important that we keep patients as comfortable and nourished as possible during this tough treatment regimen, to optimize clinical outcomes,” Dr. Allison stated in the press release.
Jeffrey B. Davis, president and CEO of Access Pharmaceuticals, detailed two key values of MuGard, per current clinical trials.
“Access believes this MuGard data is ground breaking and unique from at least two perspectives. First, this is the first product that has ever shown a statistically significant positive clinical benefit in managing the pain symptoms and delaying the onset of oral mucositis in the very difficult to treat head and neck cancer population,” Davis stated. “Second, the rigorous design of the MuGard trial is the first of its kind in a medical device treatment option for oral mucositis, setting a new standard in this area. The clinical and quality-of-life benefits shown in this data echoes what we hear in the marketplace and that is evidenced in the increasing commercial adoption of MuGard.”
For more information visit www.accesspharma.com
Let us hear your thoughts below: